StocktoriaBiofrontera Inc. BFRI
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-15.24
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M |
| Operating income | -$11.3M | -$17.2M | -$22.7M | -$18.6M | -$25.2M |
| Net income | -$10.5M | -$17.8M | -$20.1M | -$640,000 | -$37.7M |
| Operating cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | -$26.7M |
| Free cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | — |
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M |
| Shareholders' equity | $10.5M | $4.4M | $4.8M | $23.9M | $11.3M |
| Ratios | |||||
| Operating margin | -27.2% | -46.1% | -66.6% | -64.8% | -104.6% |
| Net margin | -25.3% | -47.6% | -59.1% | -2.2% | -156.5% |
| FCF margin | -32.0% | -27.5% | -73.1% | -56.6% | — |
| Return on assets | -36.9% | -80.4% | -72.1% | -1.3% | -70.9% |
| Return on equity | -100.5% | -400.6% | -420.0% | -2.7% | -332.6% |
| Current ratio | 1.52 | 1.72 | 1.28 | 2.06 | 3.36 |
| Revenue growth | 11.7% | 9.5% | 18.8% | 19.0% | 27.9% |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -15.24 (distress)
- Working capital / assets 0.217
- Retained earnings / assets -4.479
- EBIT / assets -0.397
- Equity / liabilities 0.58
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001858685 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.